研究成果の検索

検索コンセプト
選択されたフィルター

出版年

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

著者

  • Isamu Okamoto
2019

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Yonesaka, K., Iwama, E., Hayashi, H., Suzuki, S., Kato, R., Watanabe, S., Takahama, T., Tanizaki, J., Tanaka, K., Takeda, M., Sakai, K., Azuma, K., Chiba, Y., Atagi, S., Nishio, K., Okamoto, I. & Nakagawa, K., 12 1 2019, : : Scientific reports. 9, 1, 19501.

研究成果: ジャーナルへの寄稿記事

公開

Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti–PD-1 therapy

Ikematsu, Y., Tanaka, K., Yanagihara, T., Liu, R., Inoue, H., Yoneshima, Y., Ota, K., Iwama, E., Takata, S., Hata, K., Takahata, Y., Wataya, H., Nakanishi, Y. & Okamoto, I., 12 2019, : : Lung Cancer. 138, p. 58-64 7 p.

研究成果: ジャーナルへの寄稿記事

Molecularly-targeted therapies for advanced non-small-cell lung cancer

Okamoto, I., 11 25 2019, : : Japanese Journal of Lung Cancer. 59, p. 1115-1118 4 p.

研究成果: ジャーナルへの寄稿記事

公開
2020

Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation

Tsutsumi, H., Yoneshima, Y., Ota, K., Otsubo, K., Iwama, E., Inoue, H., Tanaka, K., Nakanishi, Y. & Okamoto, I., 1 2020, : : Clinical Lung Cancer. 21, 1, p. e21-e24

研究成果: ジャーナルへの寄稿記事

2016

MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy

Kawakami, H. & Okamoto, I., 7 1 2016, : : Gastric Cancer. 19, 3, p. 687-695 9 p.

研究成果: ジャーナルへの寄稿記事

12 引用 (Scopus)

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial

Takeda, M., Yamanaka, T., Seto, T., Hayashi, H., Azuma, K., Okada, M., Sugawara, S., Daga, H., Hirashima, T., Yonesaka, K., Urata, Y., Murakami, H., Saito, H., Kubo, A., Sawa, T., Miyahara, E., Nogami, N., Nakagawa, K., Nakanishi, Y. & Okamoto, I., 4 1 2016, : : Cancer. 122, 7, p. 1050-1059 10 p.

研究成果: ジャーナルへの寄稿記事

31 引用 (Scopus)
2017

Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A)

Fukuda, M., Shimada, M., Kitazaki, T., Nagashima, S., Hashiguchi, K., Ebi, N., Takayama, K., Nakanishi, Y., Semba, H., Harada, T., Seto, T., Okamoto, I., Ichinose, Y. & Sugio, K., 1 1 2017, : : Thoracic Cancer. 8, 1, p. 40-45 6 p.

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Yoneshima, Y., Morita, S., Ando, M., Miura, S., Yoshioka, H., Abe, T., Kato, T., Kondo, M., Hosomi, Y., Hotta, K., Yamamoto, N., Kishimoto, J., Nakanishi, Y. & Okamoto, I., 1 1 2017, : : Clinical Lung Cancer. 18, 1, p. 100-103 4 p.

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)
2016

Characteristics of smoking patients with lung cancer with emphysematous bullae

Iwama, E., Okamoto, I., Yabuuchi, H., Takayama, K., Harada, T., Matsuo, Y., Tokunaga, S., Baba, E. & Nakanishi, Y., 1 1 2016, : : Journal of Thoracic Oncology. 11, 9, p. 1586-1590 5 p.

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)
2017

Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies

Okamoto, I., Schuette, W. H. W., Stinchcombe, T. E., Rodrigues-Pereira, J., San Antonio, B., Chen, J., Liu, J., John, W. J. & Zinner, R. G., 5 4 2017, : : Current Medical Research and Opinion. 33, 5, p. 937-941 5 p.

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)
2019

Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies

Yoneshima, Y., Tanaka, K., Shiraishi, Y., Hata, K., Watanabe, H., Harada, T., Otsubo, K., Iwama, E., Inoue, H., Masuda, S., Nakanishi, Y. & Okamoto, I., 4 2019, : : Lung Cancer. 130, p. 5-9 5 p.

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

Park, K., Wan-Teck Lim, D., Okamoto, I. & Yang, J. C. H., 4 1 2019, : : Therapeutic Advances in Medical Oncology. 11

研究成果: ジャーナルへの寄稿評論記事

公開
2 引用 (Scopus)
2017

Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab

Otsubo, K., Nakatomi, K., Furukawa, R., Ashida, K., Yoneshima, Y., Nakanishi, Y. & Okamoto, I., 12 1 2017, : : Annals of Oncology. 28, 12, p. 3106-3107 2 p.

研究成果: ジャーナルへの寄稿レター

7 引用 (Scopus)

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

Iwama, E., Sakai, K., Azuma, K., Harada, T., Harada, D., Nosaki, K., Hotta, K., Ohyanagi, F., Kurata, T., Fukuhara, T., Akamatsu, H., Goto, K., Shimose, T., Kishimoto, J., Nakanishi, Y., Nishio, K. & Okamoto, I., 1 1 2017, : : Annals of Oncology. 28, 1, p. 136-141 6 p.

研究成果: ジャーナルへの寄稿記事

28 引用 (Scopus)
2019

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia

DLD/TO Assemblies of JRS, 11 2019, : : Respiratory Investigation. 57, 6, p. 512-533 22 p.

研究成果: ジャーナルへの寄稿評論記事

1 引用 (Scopus)
2018

CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer

Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., Okamoto, I., Leighl, N., Hodge, R., McKeown, A., Brown, A. P., Rukazenkov, Y., Ramalingam, S. S. & Vansteenkiste, J., 11 20 2018, : : Journal of Clinical Oncology. 36, 33, p. 3290-3297 8 p.

研究成果: ジャーナルへの寄稿記事

71 引用 (Scopus)
2019

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Ohe, Y., Imamura, F., Nogami, N., Okamoto, I., Kurata, T., Kato, T., Sugawara, S., Ramalingam, S. S., Uchida, H., Hodge, R., Vowler, S. L., Walding, A. & Nakagawa, K., 1 1 2019, : : Japanese journal of clinical oncology. 49, 1, p. 29-36 8 p.

研究成果: ジャーナルへの寄稿記事

7 引用 (Scopus)
2016

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Yang, J. C. H., Sequist, L. V., Zhou, C., Schuler, M., Geater, S. L., Mok, T., Hu, C. P., Yamamoto, N., Feng, J., O'Byrne, K., Lu, S., Hirsh, V., Huang, Y., Sebastian, M., Okamoto, I., Dickgreber, N., Shah, R., Märten, A., Massey, D., Wind, S. および1人, Wu, Y. L., 1 1 2016, : : Annals of Oncology. 27, 11, p. 2103-2110 8 p.

研究成果: ジャーナルへの寄稿記事

74 引用 (Scopus)
2018

Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non–Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis

Otsubo, K., Kishimoto, J., Kenmotsu, H., Minegishi, Y., Ichihara, E., Shiraki, A., Kato, T., Atagi, S., Horinouchi, H., Ando, M., Kondoh, Y., Kusumoto, M., Ichikado, K., Yamamoto, N., Nakanishi, Y. & Okamoto, I., 1 2018, : : Clinical Lung Cancer. 19, 1, p. e5-e9

研究成果: ジャーナルへの寄稿記事

19 引用 (Scopus)
2019
16 引用 (Scopus)

Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis

Hirashima, T., Satouchi, M., Hida, T., Nishio, M., Kato, T., Sakai, H., Imamura, F., Kiura, K., Okamoto, I., Kasahara, K., Uchida, H., Vowler, S. L. & Mitsudomi, T., 9 1 2019, : : Cancer Science. 110, 9, p. 2884-2893 10 p.

研究成果: ジャーナルへの寄稿記事

公開
2 引用 (Scopus)

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K. & Mitsudomi, T., 12 1 2019, : : Annals of Oncology. 30, 12, p. 1978-1984 7 p.

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)
2018

Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. C., Gray, J. E., Lee, S. M. および4人, Hodge, R., Marotti, M., Rukazenkov, Y. & Ramalingam, S. S., 1 11 2018, : : New England Journal of Medicine. 378, 2, p. 113-125 13 p.

研究成果: ジャーナルへの寄稿記事

768 引用 (Scopus)

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

Iwama, E., Nakanishi, Y. & Okamoto, I., 3 4 2018, : : Expert Review of Anticancer Therapy. 18, 3, p. 267-276 10 p.

研究成果: ジャーナルへの寄稿評論記事

5 引用 (Scopus)

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements

Yoneshima, Y., Ijichi, K., Anai, S., Ota, K., Otsubo, K., Iwama, E., Tanaka, K., Oda, Y., Nakanishi, Y. & Okamoto, I., 4 2018, : : Lung Cancer. 118, p. 36-40 5 p.

研究成果: ジャーナルへの寄稿記事

19 引用 (Scopus)

PD-L2 expression as a potential predictive biomarker for the response to anti-PD-1 drugs in patients with non-small cell lung cancer

Takamori, S., Takada, K., Toyokawa, G., Azuma, K., Shimokawa, M., Jogo, T., Yamada, Y., Hirai, F., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., 10 2018, : : Anticancer research. 38, 10, p. 5897-5901 5 p.

研究成果: ジャーナルへの寄稿記事

9 引用 (Scopus)

Prognostic impact of PD-L2 expression and association with PD-L1 in patients with small-cell lung cancer

Takamori, S., Takada, K., Azuma, K., Jogo, Y., Kinoshita, F., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Toyokawa, G., Hirai, F., Tagawa, T., Okamoto, I., Nakanishi, Y., Kawahara, A., Akiba, J., Oda, Y. & Maehara, Y., 10 2018, : : Anticancer research. 38, 10, p. 5903-5907 5 p.

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)
2019

18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer

Takada, K., Toyokawa, G., Yoneshima, Y., Tanaka, K., Okamoto, I., Shimokawa, M., Wakasu, S., Haro, A., Osoegawa, A., Tagawa, T., Oda, Y., Nakanishi, Y. & Mori, M., 12 1 2019, : : Scientific reports. 9, 1, 13362.

研究成果: ジャーナルへの寄稿記事

公開
1 引用 (Scopus)
2018

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade

Tanaka, K., Yanagihara, T., Ikematsu, Y., Inoue, H., Ota, K., Kashiwagi, E., Suzuki, K., Hamada, N., Takeuchi, A., Tatsugami, K., Eto, M., Ijichi, K., Oda, Y., Otsubo, K., Yoneshima, Y., Iwama, E., Nakanishi, Y. & Okamoto, I., 7 17 2018, : : Oncotarget. 9, 55, p. 30587-30593 7 p.

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)
2019

Identification of genomic alterations acquired during treatment with EGFR-TKIs in non-small cell lung cancer

Kubo, N., Harada, T., Shiraishi, Y., Nosaki, K., Nakagaki, N., Takeshita, M., Ouchi, H., Iwama, E., Tanaka, K., Okamoto, I., Sasaki, H. & Nakanishi, Y., 2 2019, : : Anticancer research. 39, 2, p. 671-677 7 p.

研究成果: ジャーナルへの寄稿記事

2017

Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer

Hidaka, N., Iwama, E., Kubo, N., Harada, T., Miyawaki, K., Tanaka, K., Okamoto, I., Baba, E., Akashi, K., Sasaki, H. & Nakanishi, Y., 6 1 2017, : : Lung Cancer. 108, p. 75-82 8 p.

研究成果: ジャーナルへの寄稿記事

18 引用 (Scopus)

Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Ogata, H., Okamoto, I., Yoshimoto, G., Obara, T., Ijichi, K., Iwama, E., Harada, T., Akashi, K. & Nakanishi, Y., 3 1 2017, : : Respiratory Investigation. 55, 2, p. 181-183 3 p.

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)
2020

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study

Senan, S., Okamoto, I., Lee, G. W., Chen, Y., Niho, S., Mak, G., Yao, W., Shire, N., Jiang, H. & Cho, B. C., 3 2020, : : Clinical Lung Cancer. 21, 2, p. e84-e88

研究成果: ジャーナルへの寄稿記事

公開
2018
1 引用 (Scopus)

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples

Kiura, K., Yoh, K., Katakami, N., Nogami, N., Kasahara, K., Takahashi, T., Okamoto, I., Cantarini, M., Hodge, R. & Uchida, H., 4 2018, : : Cancer Science. 109, 4, p. 1177-1184 8 p.

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)
2017

CD44 variant–dependent regulation of redox balance in EGFR mutation–positive non–small cell lung cancer: A target for treatment

Kawano, Y., Iwama, E., Tsuchihashi, K., Shibahara, D., Harada, T., Tanaka, K., Nagano, O., Saya, H., Nakanishi, Y. & Okamoto, I., 11 2017, : : Lung Cancer. 113, p. 72-78 7 p.

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)
2018

Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer

Kimura, S., Harada, T., Ijichi, K., Tanaka, K., Liu, R., Shibahara, D., Kawano, Y., Otsubo, K., Yoneshima, Y., Iwama, E., Nakanishi, Y. & Okamoto, I., 6 2018, : : Lung Cancer. 120, p. 98-107 10 p.

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)
2019

Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor

Hino, T., Kamitani, T., Sagiyama, K., Yamasaki, Y., Okamoto, I., Tagawa, T., Ijichi, K., Yamamoto, H., Yabuuchi, H. & Honda, H., 1 1 2019, : : European Journal of Radiology Open. 6, p. 72-77 6 p.

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)
2018

Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer

Otsubo, K., Seki, N., Nakanishi, Y. & Okamoto, I., 3 1 2018, : : Annals of Oncology. 29, 3, p. 780-781 2 p.

研究成果: ジャーナルへの寄稿レター

1 引用 (Scopus)

Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer

Kawano, Y., Sasaki, T., Yamaguchi, H., Hirano, K., Horiike, A., Satouchi, M., Hosokawa, S., Morinaga, R., Komiya, K., Inoue, K., Fujita, Y., Toyozawa, R., Kimura, T., Takahashi, K., Nishikawa, K., Kishimoto, J., Nakanishi, Y. & Okamoto, I., 11 2018, : : Lung Cancer. 125, p. 136-141 6 p.

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)
2019

Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer

Tsuchiya-Kawano, Y., Sasaki, T., Yamaguchi, H., Hirano, K., Horiike, A., Satouchi, M., Hosokawa, S., Morinaga, R., Komiya, K., Inoue, K., Fujita, Y., Toyozawa, R., Kimura, T., Takahashi, K., Nishikawa, K., Kishimoto, J., Nakanishi, Y. & Okamoto, I., 1 1 2019, (受理済み/印刷中) : : Oncologist.

研究成果: ジャーナルへの寄稿記事

公開
2018

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial

Akamatsu, H., Katakami, N., Okamoto, I., Kato, T., Kim, Y. H., Imamura, F., Shinkai, M., Hodge, R. A., Uchida, H. & Hida, T., 6 2018, : : Cancer Science. 109, 6, p. 1930-1938 9 p.

研究成果: ジャーナルへの寄稿記事

17 引用 (Scopus)
2020

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

Iwama, E., Sakai, K., Hidaka, N., Inoue, K., Fujii, A., Nakagaki, N., Ota, K., Toyozawa, R., Azuma, K., Nakatomi, K., Harada, T., Hisasue, J., Sakata, S., Shimose, T., Kishimoto, J., Nakanishi, Y., Nishio, K. & Okamoto, I., 1 1 2020, : : Cancer. 126, 1, p. 219-227 9 p.

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)
2016

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: A retrospective analysis for 1660 Japanese patients

Inoue, A., Yoshida, K., Morita, S., Imamura, F., Seto, T., Okamoto, I., Nakagawa, K., Yamamoto, N., Muto, S. & Fukuoka, M., 1 1 2016, : : Japanese journal of clinical oncology. 46, 5, p. 462-467 6 p.

研究成果: ジャーナルへの寄稿記事

29 引用 (Scopus)
2019

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401

Iwama, E., Goto, Y., Murakami, H., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., Bessho, A., Ono, M., Nishitsuji, M., Akamatsu, H., Morinaga, R., Akagi, T., Shimose, T., Tokunaga, S., Yamamoto, N., Nakanishi, Y., Sugio, K. および1人, Okamoto, I., 1 1 2019, (受理済み/印刷中) : : Oncologist.

研究成果: ジャーナルへの寄稿記事

公開

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

Sugawara, S., Nakagawa, K., Yamamoto, N., Nokihara, H., Ohe, Y., Nishio, M., Takahashi, T., Goto, K., Maemondo, M., Ichinose, Y., Seto, T., Sakai, H., Gemma, A., Imamura, F., Shingyoji, M., Saka, H., Inoue, A., Takeda, K., Okamoto, I., Kiura, K. および2人, Morita, S. & Tamura, T., 5 15 2019, : : International Journal of Clinical Oncology. 24, 5, p. 485-493 9 p.

研究成果: ジャーナルへの寄稿記事

公開
2016

Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study

Nosaki, K., Satouchi, M., Kurata, T., Yoshida, T., Okamoto, I., Katakami, N., Imamura, F., Tanaka, K., Yamane, Y., Yamamoto, N., Kato, T., Kiura, K., Saka, H., Yoshioka, H., Watanabe, K., Mizuno, K. & Seto, T., 11 1 2016, : : Lung Cancer. 101, p. 1-8 8 p.

研究成果: ジャーナルへの寄稿記事

55 引用 (Scopus)
2019

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., Chiu, C. H., Park, K., Novello, S., Nadal, E., Imamura, F., Yoh, K., Shih, J. Y., Au, K. H., Moro-Sibilot, D., Enatsu, S., Zimmermann, A., Frimodt-Moller, B., Visseren-Grul, C., Reck, M. および96人, Chu, Q., Cortot, A., Pujol, J. L., Fabre, E., Lamour, C., Bischoff, H., Kollmeier, J., Kimmich, M., Engel-Riedel, W., Hammerschmidt, S., Schütte, W., Syrigos, K., Ho, J. C. M., Au, K. H., Ardizzoni, A., Pasello, G., Gregorc, V., Del Conte, A., Galetta, D., Takahashi, T., Kumagai, T., Hotta, K., Goto, Y., Hosomi, Y., Sakai, H., Takiguchi, Y., Kim, Y. H., Kurata, T., Yamaguchi, H., Daga, H., Okamoto, I., Satouchi, M., Ikeda, S., Kasahara, K., Atagi, S., Azuma, K., Aoe, K., Horio, Y., Yamamoto, N., Tanaka, H., Watanabe, S., Nogami, N., Ozaki, T., Koyama, R., Hirashima, T., Kaneda, H., Tomii, K., Fujita, Y., Seike, M., Nishimura, N., Kato, T., Ichiki, M., Saka, H., Hirano, K., Nakahara, Y., Sugawara, S., Kim, S. W., Min, Y. J., Lee, H. W., Kang, J. H., An, H. J., Lee, K. H., Kim, J. S., Lee, G. W., Lee, S. Y., Alexandru, A., Udrea, A. A., Juan-Vidal, Ó., Nadal-Alforja, E., Gil-Bazo, I., Ponce-Aix, S., Rubio-Viqueira, B., Alonso Garcia, M., Felip Font, E., Fuentes Pradera, J., Coves Sarto, J., Lin, M. C., Su, W. C., Hsia, T. C., Chang, G. C., Wei, Y. F., Su, J., Cicin, I., Goksel, T., Harputluoglu, H., Ozyilkan, O., Henning, I., Popat, S., Hatcher, O., Mileham, K., Acoba, J., Garon, E., Jung, G., Raj, M., Martin, W. & Dakhil, S., 12 2019, : : The Lancet Oncology. 20, 12, p. 1655-1669 15 p.

研究成果: ジャーナルへの寄稿記事

7 引用 (Scopus)
2018

Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

Kato, T., Seto, T., Nishio, M., Goto, K., Yamamoto, N., Okamoto, I., Tao, L., Yu, W., Khaznadar, T., Tajima, K., Shibata, M., Seki, A. & Yamamoto, N., 2 1 2018, : : Drug Safety. 41, 2, p. 229-237 9 p.

研究成果: ジャーナルへの寄稿記事

12 引用 (Scopus)